Therapeutic delivery of LNAs targeting LINK-A 17 and BCAR4 167, 168 has been proven to sensitize BC to immune checkpoint inhibitors and attenuate BC growth and metastasis in vivo, respectively. This evidence concerns the gene BCAR4 and breast cancer.